Targeting p53 for Melanoma Treatment: Counteracting Tumour Proliferation, Dissemination and Therapeutic Resistance

Targeting KIT for Treatment Of Advanced Melanoma

This is a remarkable time for melanoma research and treatment. Before this year, approved agents available for the treatment of metastatic melanoma were limited to dacarbazine (DTIC) and interleukin-2 (IL-2), with benefits achieved in only a small minority of patients treated with either drug. In 2011, however, two new agents, ipilimumab (YervoyTM) and vemurafenib (ZelborafTM), were approved, w...

S2. Therapeutic strategies based on overcoming immune resistance mechanisms within the melanoma tumour microenvironment

Two major categories of melanoma metastases have been observed based on gene expression profiling and confirmatory assays. One subgroup of patients has an inflamed phenotype that includes expression of chemokines, T cell markers, and other immunoregulatory factors. In contrast, the other major subset lacks this phenotype and appears to display immune “exclusion”. The optimal immunotherapeutic i...

Antibiotic resistance dissemination and sewage treatment plants

Antibiotics are a class of naturally-occurring and synthetic chemical compounds with antimicrobial activity and are widely used in human and veterinary medicine. The increasing incidence of resistance to a wide range of antibiotic agents by a variety of organisms is a major concern facing modern medicine. There is widespread speculation that sewage treatment plants (STPs) and aquatic environmen...

Targeting autophagy as a potential therapeutic approach for melanoma therapy.

Melanoma, occurring as a rapidly progressive skin cancer, is resistant to current chemo- and radiotherapy, especially after metastases to distant organs has taken place. Most chemotherapeutic drugs exert their cytotoxic effect by inducing apoptosis, which, however, is often deficient in cancer cells. Thus, it is appropriate to attempt the targeting of alternative pathways, which regulate cellul...

Therapeutic Targeting and Clinical Assessment of the Tumour Vasculature